Loading viewer...
investor_presentation
Format: PDF investor_presentation
1 ©2022 KARYOPHARM THERAPEUTICS INC. Third Quarter 2022 Financial Results & Business Update November 3, 2022
1 ©2022 KARYOPHARM THERAPEUTICS INC.
November 3, 2022 2 ©2022 KARYOPHARM THERAPEUTICS INC. On Today’s Call
Elhan Webb, CFA, Senior Vice President, Investor Relations
Richard Paulson, President and Chief Executive Officer
•Commercial Highlights
Sohanya Cheng, Chief Commercial Officer
Dr. Reshma Rangwala , Chief Medical Officer
•Financial Summary and Guidance
Michael Mason, Chief Financial Officer
Richard Paulson, President and Chief Executive Officer
•Q&A Session 3 ©2022 KARYOPHARM THERAPEUTICS INC. Forward -looking Statements and Other Important Information
This presentation contains forward -looking statements within themeaning ofThe Private Securities Litigation Reform Actof1995 .Such forward -looking statements include those regarding
Karyopharm’s financial guidance forfullyear 2022 ;Karyopharm’s expected cash runway ;theability ofselinexor oreltanexor totreat patients with multiple myeloma, diffuse large B-celllymphoma,
myelofibrosis, myelodysplastic syndromes, solid tumors andother diseases ;andexpectations related tofuture clinical development andpotential regulatory submissions ofselinexor andeltanexor .
Such statements aresubject tonumerous important factors, risks anduncertainties, many ofwhich arebeyond Karyopharm's control, thatmay cause actual events orresults todiffer materially from
Karyopharm's current expectations .Forexample, there canbenoguarantee that Karyopharm willsuccessfully commercialize XPOVIO orthat anyofKaryopharm’s drug candidates, including
selinexor and eltanexor, willsuccessfully complete necessary clinical development phases orthatdevelopment ofanyofKaryopharm’s drug candidates willcontinue .Further, there canbeno
guarantee thatanypositive developments inthedevelopment orcommercialization ofKaryopharm’s drug candidate portfolio willresult instock price appreciation .Management’s expectations and,
therefore, anyforward -looking statements inthispress release could also beaffected byrisks anduncertainties relating toanumber ofother factors, including thefollowing :theriskthattheCOVID -19
pandemic could disrupt Karyopharm’s business more severely than itcurrently anticipates, including bynegatively impacting sales ofXPOVIO, interrupting ordelaying research anddevelopment
efforts, impacting theability toprocure sufficient supply forthedevelopment andcommercialization ofselinexor orother product candidates, delaying ongoing orplanned clinical trials, impeding the
execution ofbusiness plans, planned regulatory milestones andtimelines, orinconveniencing patients ;theadoption ofXPOVIO inthecommercial marketplace, thetiming andcosts involved in
commercializing XPOVIO oranyofKaryopharm’s drug candidates thatreceive regulatory approval ;theability toobtain and retain regulatory approval ofXPOVIO oranyofKaryopharm’s drug
candidates thatreceive regulatory approval ;Karyopharm's results ofclinical trials andpreclinical studies, including subsequent analysis ofexisting data andnew data received from ongoing andfuture
Preview truncated — download the full document for the complete content.
conference
34 Pages
investor_presentation
12 Pages
INOVIQ Limited